Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Total Current Liabilities (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Total Current Liabilities for 13 consecutive years, with $19.9 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 10.98% to $19.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.9 million through Dec 2025, up 10.98% year-over-year, with the annual reading at $19.9 million for FY2025, 10.98% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $19.9 million at Niagen Bioscience, down from $22.7 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $22.7 million in Q3 2025, with the low at $16.2 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $18.9 million, with a median of $18.4 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities fell 12.97% in 2024, then grew 28.32% in 2025.
  • Over 5 years, Total Current Liabilities stood at $17.6 million in 2021, then rose by 1.45% to $17.9 million in 2022, then rose by 15.41% to $20.6 million in 2023, then dropped by 12.97% to $17.9 million in 2024, then increased by 10.98% to $19.9 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $19.9 million, $22.7 million, and $22.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.